Table 2.
Complications.
| Complications | ATG-F | Thymoglobulin | P |
|---|---|---|---|
| n = 15 | n = 15 | ||
| Adverse effect of antilymphocyte globulin perfusion, n (%) | 4 (27) | 8 (53) | 0.14 |
|
| |||
| Graft failure, n (%) | 1 (7) | 1 (7) | 1.00 |
|
| |||
| Rejection, n (%) | 2 (13) | 3 (20) | 1.00 |
|
| |||
| Relapse, n (%) | 5 (33) | 7 (47) | 0.46 |
|
| |||
| Cumulative incidence of relapse at 3 years (%) | 33.3 (16.3–68.2) | 40 (21.5–74.3) | 0.55 |
|
| |||
| CMV reactivation, n (%) | 11 (73) | 10 (67) | 0.69 |
|
| |||
| Severe infection after aplasia, n patients (%) | 9 (60) | 7 (47) | 0.46 |
|
| |||
| Respiratory infections, n | 2 RSV 1 Staph. aureus pneumonia |
2 H1N1 influenza 2 bacterial pneumonia 1 invasive lung aspergillosis |
|
|
| |||
| Bacteremia, n | 2 Staphylococcus
1 Kytococcus schroeteri |
1 multiple (E. coli, Pseudomonas sp., Listeria monocytogenes) |
|
|
| |||
| Other infections, n | 3 BK-virus cystitis 1 Microsporidiosis 3 E. coli urinary 1 HHV-6 encephalitis 2 genital HSV-1 |
1 gastroenteritis 1 acute middle otitis 1 generalized aspergillosis 1 large spectrum beta-lactamase enterobacteria urinary |
|
|
| |||
| Acute GvHD grade I, n (%) | 2 (13) | 2 (13) | 1.00 |
|
| |||
| Acute GvHD grades II–IV, n (%) | 6 (40) | 3 (20) | 0.23 |
|
| |||
| Cumulative incidence of aGvHD grades I–IV at day 100 (%) | 53.3 (33.2–85.6) | 26.7 (11.5–61.7) | 0.23 |
|
| |||
| Chronic limited GvHD, n (%) | 0 | 1 (7) | 1.00 |
|
| |||
| Chronic extensive GvHD, n (%) | 4 (27) | 3 (20) | 0.67 |
|
| |||
| Cumulative incidence of cGvHD at 3 years (%) | 13.3 (3.7–48.5) | 20.0 (7.3–55.0) | 0.87 |
|
| |||
| Death, n (%) | 8 (53) | 8 (53) | 1.00 |
|
| |||
| TRM, cumulative incidence at 3 years (%) | 33.3 (16.3–68.2) | 20 (7.3–55) | 0.67 |
|
| |||
| OS, cumulative incidence at 3 years (%) | 46.7 (20.7–72.7) | 45.7 (19.7–71.7) | 0.97 |
|
| |||
| DFS, cumulative incidence at 3 years (%) | 33.7 (8.9–58.1) | 40.0 (14.8–65.2) | 0.86 |